JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Walmart and CVS ink a deal, American Express falls short, Apple partners with pharma giant
    Yahoo Finance Video9 hours ago

    Walmart and CVS ink a deal, American Express falls short, Apple partners with pharma giant

    Walmart, CVS, American Express, Apple, Johnson & Johnson, Rio Tinto and Tribune Publishing are the companies to watch.

  • Walmart and CVS ink a deal, American Express falls short, Apple partners with pharma giant
    Yahoo Finance9 hours ago

    Walmart and CVS ink a deal, American Express falls short, Apple partners with pharma giant

    Walmart, CVS, American Express, Apple, Johnson & Johnson, Rio Tinto and Tribune Publishing are the companies to watch.

  • TheStreet.com23 minutes ago

    New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

    Twelve weeks a year, investors need to be on the top of their game, Jim Cramer told his Mad Money viewers Friday. Cramer remained a fan of the deal. Cramer was a fan of Comcast's bid to buy Sky, and also liked the outlooks for both Procter and the very consistent Abbott Labs.

  • CNBC1 hour ago

    Cramer's game plan: This week, forecasts are more important than earnings

    CNBC's Jim Cramer looks ahead at a busy week of earnings reports that he says might drive investors crazy. Johnson & Johnson, Comcast and Starbucks will be among the companies issuing quarterly results. "I can't recall a time when the forecast will be more important, certainly much more important than the results," Cramer, host of "Mad Money," told viewers.

  • Reuters2 hours ago

    AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

    AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, Imbruvica, failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of placebo and two chemotherapy agents. The American Cancer society estimates that pancreatic cancer accounts for about 3 percent of all cancers in the United States and about 7 percent of all cancer deaths, and expects that 56,770 people will be diagnosed with pancreatic cancer in 2019.

  • What Happened in the Stock Market Today
    Motley Fool2 hours ago

    What Happened in the Stock Market Today

    The major benchmarks made gains, but Netflix fell despite reporting a strong quarter. Elsewhere, Apple and Johnson & Johnson announced a new collaboration.

  • TheStreet.com3 hours ago

    16 Stocks Jim Cramer Says Could Win from a U.S.-Chinese Trade Deal

    What about all of the intelligentsia that come on air and tell us that the Chinese are playing the long game and we'll lose in the end? Well, I think they aren't businesspeople. What's really amazing is how universally contemptuous businesspeople are of the Chinese.

  • Key Takeaways from Q4 Earnings Results Thus Far
    Zacks3 hours ago

    Key Takeaways from Q4 Earnings Results Thus Far

    Key Takeaways from Q4 Earnings Results Thus Far

  • Apple Expands in Healthcare, Partners Johnson & Johnson
    Zacks4 hours ago

    Apple Expands in Healthcare, Partners Johnson & Johnson

    Apple (AAPL) partners with Johnson & Johnson to conduct multi-year research study for early detection of irregular heart conditions.

  • The Dogs of the Dow 2019: 10 Dividend Stocks to Watch
    Kiplinger5 hours ago

    The Dogs of the Dow 2019: 10 Dividend Stocks to Watch

    The "Dogs of the Dow" is a simple but successful value investing strategy that many on Wall Street swear by. It's easy: At the beginning of the year, buy the 10 highest-yielding dividend stocks in the Dow Jones Industrial Average. Hold them for a year. Next year, rinse and repeat. While this does result in higher-than-average income, the investment case really is a value one. The idea: A high dividend yield - in the kind of rock-solid blue-chip stocks the Dow tends to hold - implies that shares are oversold. Meanwhile, the continued payment of dividends shows that management remains confident in the company's earnings. Investors thus should profit both from an above-average yield, as well as an eventual recovery in share prices once Wall Street realizes its selling has gone too far. How well does the strategy work? In 2018, the Dogs of the Dow lost just 1.5% on average versus a 5.6% decline for the Dow and a 6.2% drop for the Standard & Poor's 500-stock index. The win marked the Dogs' fourth consecutive year of outperformance. And already in 2019, some Dogs are baring their fangs. Here are the 10 dividend stocks that make up the Dogs of the Dow, listed in order of their dividend yields as of the start of 2019. We also list their current yields, which have shifted a bit in the first few days of this year's trading. ### SEE ALSO: The 25 Best S&P; 500 Stocks of the Past 50 Years

  • Top Stock Reports for Pfizer, Biogen & Schwab
    Zacks5 hours ago

    Top Stock Reports for Pfizer, Biogen & Schwab

    Top Stock Reports for Pfizer, Biogen & Schwab